The Safety and Efficacy of GLP-1 Receptor Agonists in Heart Failure Patients: A Systematic Review and Meta-Analysis |
| |
| Affiliation: | 1. Department of Internal Medicine, University of Toledo, Ohio, USA;2. Allama Iqbal Medical College, Lahore, Pakistan;3. Fatima Jinnah Medical University, Lahore, Pakistan;4. Jinnah Sindh Medical University, Karachi, Pakistan;5. Sharif Medical and Dental College, Lahore, Pakistan;6. King Edward Medical University, Lahore, Pakistan;7. Shaheed Mohtarma Benazir Bhutto Medical College, Karachi, Pakistan;8. Department of Internal Medicine, University of California, Riverside School of Medicine, Riverside, CA, USA;1. Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Av. Professor Egas Moniz, 1649-028 Lisbon, Portugal;2. University Hospital Santa Maria, Department of Cardiology, Lisbon Academic Medical Centre, CCUL, Lisbon University, Lisbon, Portugal;3. Programme for Advanced Medical Education, Fundação Calouste Gulbenkian, Ministry of Health and Foundation for Science and Technology, Lisbon, Portugal;4. University Hospital Santa Maria, Department of Cardiothoracic Surgery, Lisbon Academic Medical Centre, CCUL, Lisbon University, Lisbon, Portugal;1. Department of Radiology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China;2. Department of Magnetic Resonance Imaging, Fuwai Hospital and National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China;3. Department of Radiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China;4. Department of Radiology, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China;1. Division of Clinical Pharmacology, Centre for Interdisciplinary Research on Medicines (CIRM), University of Liège, Liège, Belgium;2. Department of Medicine, Division of Diabetes, Nutrition and Metabolic Disorders, CHU Liège, Liège, Belgium |
| |
| Abstract: | Evaluation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) usage in heart failure (HF) patients with or without type 2 diabetes mellitus (T2DM) could be proven to be a critical breakthrough in treatment options available for these patients. Our study focuses on understanding the safety and efficacy of GLP-1 RAs in this patient population by pooling the data from 9 randomized controlled trials (RCTs) comprising 871 subjects. As compared with the placebo, GLP-1 RAs did not improve major adverse cardiovascular events (MACE) which include cardiovascular (CV) mortality and heart failure (HF) hospitalizations, our primary outcome. CV mortality (RR = 1.03, 95% CI = 0.56-1.88, P = 0.92) and HF hospitalizations (RR = 1.18, 95%CI = 0.93-1.51, P = 0.18). Similarly, GLP-1 RAs did not improve our secondary findings of left ventricular ejection fraction (LVEF) and 6-minute walk test (6MWT). LVEF (RR = 1.96, 95%CI = ?0.16-4.07, P = 0.07) or 6 MWT (RR = 8.43, 95% CI = ?2.69-19.56, P = 0.14). This meta-analysis shows that GLP-1 RAs do not improve cardiovascular outcomes in HF patients with or without T2DM. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
